SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Wedbush Raises Beam Therapeutics Price Target to $30 From $28

Wedbush kept its Outperform rating on Beam Therapeutics.

BEAM

Related stories